CHANNEL THERAPEUTICS CORP (CHRO) Stock Price & Overview
NYSEARCA:CHRO • US1711261057
Current stock price
The current stock price of CHRO is 1.35 USD. Today CHRO is up by 7.14%. In the past month the price increased by 32.35%. In the past year, price increased by 9.76%.
CHRO Key Statistics
- Market Cap
- 8.141M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.28
- Dividend Yield
- N/A
CHRO Stock Performance
CHRO Stock Chart
CHRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CHRO. When comparing the yearly performance of all stocks, CHRO turns out to be only a medium performer in the overall market: it outperformed 42.86% of all stocks.
CHRO Earnings
CHRO Forecast & Estimates
CHRO Groups
Sector & Classification
CHRO Financial Highlights
Over the last trailing twelve months CHRO reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -197.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -810.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CHRO Ownership
CHRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CHRO
Company Profile
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Company Info
IPO: 2024-02-16
CHANNEL THERAPEUTICS CORP
685 US Highway One
North Brunswick NEW JERSEY US
Employees: 4
Phone: 19176446313
CHANNEL THERAPEUTICS CORP / CHRO FAQ
Can you describe the business of CHANNEL THERAPEUTICS CORP?
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company is headquartered in North Brunswick, New Jersey and currently employs 4 full-time employees. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
What is the stock price of CHANNEL THERAPEUTICS CORP today?
The current stock price of CHRO is 1.35 USD. The price increased by 7.14% in the last trading session.
Does CHANNEL THERAPEUTICS CORP pay dividends?
CHRO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CHRO stock?
CHRO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of CHANNEL THERAPEUTICS CORP (CHRO) based on its PE ratio?
CHANNEL THERAPEUTICS CORP (CHRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
Would investing in CHANNEL THERAPEUTICS CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CHRO.
Can you provide the ownership details for CHRO stock?
You can find the ownership structure of CHANNEL THERAPEUTICS CORP (CHRO) on the Ownership tab.